In addition, we assessed the utility of a liver-targeted mitochondrial uncoupling agent (13–17) for the treatment of hepatic steatosis in L-Mttp−/− mice, as there are no currently available treatments for hepatic steatosis in the setting of MTTP deficiency. Here, MTTP is linked to fatty liver disease.